ABOUT SIGLA

SIGLA SCIENCES was founded to help BioPharma companies navigate the increasingly challenging waters of market access, payer interactions, and value-based care, particularly for higher-cost therapeutics in oncology, specialty, and rare disease markets.
We pair scientific and clinical expertise with a real-world, pragmatic approach to payers, access, value, and policy that can only be earned through decades in the industry working alongside the leaders in industry, academic and community medicine, health policy, patient advocacy, and payer organizations.
We also understand that companies have varied needs. For our large company and "big pharma" clients, we're happy to jump in and help alignment across multiple teams and prepare for internal as well as external presentations and milestones. For our early stage, venture-backed, and smaller biotech clients, we understand the value of being able to bring a level of polish and aesthetics typically found at large agencies into a smaller project, as well as being able to help you balance the competing priorities that arise with a pre-commercial or early commercial stage asset.

Jennifer Hinkel, MSc
Founding Partner, Sigla Sciences

Jennifer Hinkel is an oncology market access and health economics leader with experience in consulting, global pharma and biotech, health policy, and health care startups. She has held management and executive roles at companies including National Comprehensive Cancer Network, Roche UK, Roche Argentina, Genentech, and Caris Life Sciences. She is a Managing Director of The Data Economics Company where she leads commercialization of the Lydion Engine in life sciences and healthcare applications.

Previously, she was a Senior Partner at McGivney Global Advisors, where she built an oncology-focused consulting practice specializing in market access and HEOR topics. Ms. Hinkel held pricing, distribution, oncology marketing, and hospital sales roles at Roche and Genentech in the US, Latin America, and Europe. She also led financial impact assessment for the Affordable Care Act and Medicare reimbursement in Genentech's Industry Analytics group, for which she received the Genentech ACE Award. Prior to joining the biopharmaceutical industry, Ms. Hinkel held roles at National Comprehensive Cancer Network (NCCN), the Association for State and Territorial Health Officials (ASTHO), and as a researcher for a member of the United Kingdom House of Lords.

Ms. Hinkel holds degrees from the Georgia Institute of Technology (BS International Affairs) and the London School of Economics (MSc International Health Policy), and is a part-time doctoral student at the University of Oxford pursuing a DPhil in Evidence Based Health Care. She has lectured in Health Systems and Health Economics at Penn State University and Arcadia University, holds patents in health care technology, and has published numerous articles and abstracts related to market access and oncology health services research. As a survivor of Stage III Hodgkin Lymphoma, Ms. Hinkel has a special interest in oncology innovation as a cancer survivor. To support the broader survivor and oncology community, Ms. Hinkel founded Resilience Racing, the first all-cancer-survivor sailing team, and also launched the 40 Under 40 in Cancer annual awards program.

Mobirise

EMPHASIS ON VALUE

After a decade marked by incremental shifts in the access landscape and major advances in therapeutic options for oncology and specialty care, payers and integrated delivery networks (IDNs) are growing more aggressive in managing access and emphasizing “value-based” options.

Mobirise

DRIVEN BY DATA

Manufacturers are increasingly dependent on “big data” sources to make critical strategic decisions, but few companies fully understand the strengths and shortfalls of these datasets, or how to ensure that the data they are purchasing is accurate, high quality, timely, and complete.

Mobirise

EXECUTION IN PRACTICE

The Sigla team has supported 40+ biopharma, diagnostics, and digital health companies since 2014, not only as advisors, but in senior executive leadership roles during mission-critical moments. We focus on implementation, results, and impact for your product portfolio, access, and reach.

CONTACT US

Have a question, project, or just want to talk about the current access, value, policy landscape or distributed data technologies? We can't wait to chat further.

SIGLA SCIENCES

Home
About Sigla
Technology
Expertise
Case Studies

EMAIL: info at siglasciences.com